Policy options for the drug pricing conundrum

Area of Science:

• Health Economics
• Pharmaceutical Policy
• International Trade

Background:

• Current U.S. pharmaceutical pricing policies face scrutiny for high costs, particularly impacting low-income and elderly populations.
• The U.S. market significantly subsidizes global pharmaceutical prices, with U.S. drug prices exceeding those in other high-income Organization for Economic Co-operation and Development (OECD) countries by over 250%.

Purpose of the Study:

• To analyze the economic impact of proposed U.S. pharmaceutical price reductions on R&D investment.
• To model the effects of a single international pharmaceutical pricing system on global drug prices and R&D incentives.
• To explore the U.S. Medicare market as a tool for influencing international drug pricing.

Main Methods:

• Economic modeling to simulate the effects of a unified international drug price.
• Comparative analysis of U.S. drug prices versus other OECD countries.
• Analysis of pharmaceutical firm profit structures and R&D investment drivers.

Main Results:

• Immediate benefits of proposed U.S. price reductions could be offset by drastic cuts in R&D investment.
• A single international price, with fixed total profits, would halve U.S. prices.
• This pricing model would increase prices in other OECD countries (28% to over 300%) while preserving R&D incentives.

Conclusions:

• Current U.S. pricing proposals risk undermining crucial pharmaceutical R&D.
• A unified international pricing strategy, leveraging U.S. market access (e.g., Medicare), offers a mechanism to balance affordability and innovation.
• International cooperation on drug pricing is essential for a sustainable global pharmaceutical market.